Bicara Therapeutics Inc. Statistics
Want to see BCAX full AI Analyst Report?
Bicara Therapeutics Inc. (BCAX) Stock Statistics & Valuation Metrics
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $647.28M. The enterprise value is $831.00M.
- Market Cap
- $647.28M
- Enterprise Value
- $831.00M
Share Statistics
Bicara Therapeutics Inc. has 66,387,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 66,387,200
- Owned by Insiders
- 21.49%
- Owned by Institutions
- 54.01%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -38.60%.
- Return on Equity (ROE)
- -0.34
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -38.60%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.34M
- Employee Count
- 103
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is -2.73. Bicara Therapeutics Inc.’s PEG ratio is 0.07.
- PE Ratio
- -2.73
- PS Ratio
- 0.00
- PB Ratio
- 1.58
- Price to FCF
- -3.87
- Price to Operating Cash Flow
- -4.01
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0 and earned -137.95M in profits. Earnings per share was -2.52.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -155.60M
- Pretax Income
- -137.73M
- Net Income
- -137.95M
- EBITDA
- -137.63M
- Earnings Per Share (EPS)
- -2.52
Cash Flow
In the last 12 months, operating cash flow was -161.73M and capital expenditures -1.02M, giving a free cash flow of -162.75M billion.
- Operating Cash Flow
- -161.73M
- Free Cash Flow
- -162.75M
- Free Cash Flow per Share
- -2.38
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -26.13%
- Earnings Yield
- -34.34%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- -36.21%
- 50-Day Moving Average
- 16.84
- 200-Day Moving Average
- 20.94
- Relative Strength Index (RSI)
- 33.17
- Average Volume (3m)
- 1.17M
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 14.58, with Debt / Equity ratio of 0.43%
- Current Ratio
- 14.58
- Quick Ratio
- 14.58
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.69
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 217.00K in taxes.
- Income Tax
- 217.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -2.46, with an EV/FCF ratio of -3.33.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.46
- EV to Free Cash Flow
- -3.33
- EV to Operating Cash Flow
- -3.35
Balance Sheet
Bicara Therapeutics Inc. has $442.35M in cash and marketable securities with $880.00K in debt, giving a net cash position of $441.47M billion.
- Cash & Marketable Securities
- $442.35M
- Total Debt
- $880.00K
- Net Cash
- $441.47M
- Net Cash Per Share
- $6.65
- Tangible Book Value Per Share
- $5.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $31.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $31.78
- Price Target Upside
- 231.02% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -55.27%
Scores
- Smart Score
- 4
- AI Score
- 49

